PUBLICATIONS

PRICE DIFFERENCES FOR ORPHAN DRUGS ACROSS THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT

Pricing and reimbursement decisions after the European marketing authorization are the responsibility of each country, which can lead to inequalities and differences in access and prices for drugs1.

The aim of this study was to assess market access and price differences in the five European Union countries (EU5) for orphan drugs approved by the European Commission (EC)